-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Head and neck squamous cell carcinoma (HNSCC), as the seventh most common cancer in the world, is characterized by high resistance to treatment.
Although active treatments including surgery, radiotherapy and chemotherapy have shown some curative effects on the disease, the recurrence rate of patients with locally advanced HNSCC is still as high as 50%.
Head and neck squamous cell carcinoma (HNSCC), as the seventh most common cancer in the world, is characterized by high resistance to treatment.
Previous studies have shown that checkpoint inhibitor (CI) antibodies targeting PD-1 (programmed death receptor 1) or PD-L1 (programmed death ligand 1) can effectively improve the overall survival rate of patients with metastatic HNSCC , And has been approved by the FDA for treatment in combination with chemotherapy drugs.
However, only 10% to 20% of patients benefit from PD-1/PD-L1 blockade therapy.
Targeting other ways, such as co-stimulatory molecules (OX40, GITR 4-1BB, and the like), T cells may be enhanced in tumor-bearing host immune force.
Previously, there is no relevant research to explore the role of immune costimulatory agonists in neoadjuvant therapy for cancer patients.
Changes of tumor and interstitial lymphocyte infiltration after anti-OX40 treatment
In this study, the researchers reported the results of a phase Ib clinical trial (NCT02274155) in which a total of 17 locally advanced HNSCC patients received mouse anti-human OX40 agonist antibody (MEDI6469) before surgical resection.
The primary endpoint of the clinical trial is to determine the safety and feasibility of anti-OX40 neoadjuvant therapy.
The primary endpoint of the clinical trial is to determine the safety and feasibility of anti-OX40 neoadjuvant therapy.
Analysis of survival rate of patients after neoadjuvant anti-OX40 treatment
All in all, the results of the study show that anti-OX40 therapy is safe before surgery and can increase the activity and proliferation of CD4+ and CD8+ T cells in blood and tumors.
The study also showed that the increase in tumor-reactive CD103+ CD39+ CD8+ TIL may be a potential biological marker for the clinical activity of anti-OX40.
Anti-OX40 therapy is safe before surgery and can increase the activity and proliferation of CD4+ and CD8+ T cells in blood and tumors.
org/10.
Leave a message here
